和厥阴法对慢性肾衰模型干预作用的理论和实验研究
|
摘要
目的：运用厥阴病理论探讨和厥阴法治疗慢性肾衰竭的思路,以及和厥阴法对肾纤维化的干预作用。
方法：提出慢性肾衰竭厥阴阴枢不利的病机假说,以和厥阴法为治疗大法,精选药物,合理组方,制成和络泄浊颗粒,进行实验研究；采用5/6肾切除大鼠模型,将60例Wistar大鼠随机分为6组：正常组、模型组、西药福辛普利组、中药低剂量组、中剂量组及高剂量组。检测各组血清尿素氮(BUN)、血清肌酐(Scr),取残肾组织行HE染色,光镜观察肾组织病理变化,免疫组化检测细胞外基质的主要成分纤维蛋白(FN)表达的变化。逆转录聚合酶链反应(RT-PCR)及免疫组化检测转化生长因子β1(TGF-β1)、p-Smad2/3、Smad7基因及蛋白表达的变化。
结果：和络泄浊颗粒与福辛普利治疗组BUN、Scr水平明显低于模型组(P<0.05)；中西药治疗组大鼠5/6肾切除后肾组织TGF-β1、p-Smad2/3表达减弱,Smad7表达增强,肾组织FN沉积减少,肾小球硬化改善(P<0.05)。
结论：慢性肾衰竭具有厥阴阴枢不利的病机特点,和厥阴法是其重要治法；和络泄浊颗粒可调节TGF-β1/smads信号传导通路,改善肾纤维化时ECM主要成分的沉积,保护残存肾功能,延缓肾纤维化的进展。
Objective:To discusse the correlation of pathogenesis of chronic renal failure (CRF) with Jueyin disease, the thinging of treating chronic renal failure by mediating-Jueyin, and study the mechanism of the method of mediating-Jueyin interfering in renal fibrosis.
Methods:Put fotward the hypothesis that CRF are resulted from Jueyin helm malfunction. Take mediating-Jueyin as treatment method, composing the formula rationally, choosing the medicine carefully, to make the Reconciliating Collaterals and Dispersing Turbid Granula(RDG). Using 5/6 nephrectomy rats divided into 6 groups, which are normal group, model group, treated by Fuxinpuli group, treated by RDG Low-dose group(group I)、RDG middle-dose group(group II) and RDG High-dose group(group III). Observing the weight change of the rat and their biochemical results:blood urea nitrogen(BUN), serum creatinine(Scr). Take the renal tissue from the operative side. HE staining and immunohistochemical methods were used to detect the changes of Fibronectin (FN). immunohistochemical and RT-PCR methods were used to detect the changes of the gene and protein expression of transforming growth factor-β1/Smad singaling Pathway (TGF-β1/Smads).
Result:Compared with the untreated 5/6 nephrectomized group, BUN、Scr of RDG groups and Fuxinpuli group were substantially decreased (P< 0.05). The expression of TGF-β1、p-Smad2/3、FN in 5/6 nephrectomy rats is higher than in normal group. It was less in RDG groups and Fuxipuli group (P< 0.05).The expression of Smad7 in 5/6 nephrectomy rats is less than in normal group. It was higher in RDG groups and Fuxipuli group (P< 0.05). extracellular matrix(ECM) was less in RDG groups and Fuxipuli group. The glomerular sclerosis was less in RDG groups and Fuxipuli group.
Conclusion:The Jueyin helm malfunction is the pathological characteristic of CRF, the method of mediating-Jueyin is effective on it. The therapy can adjust transforming growth factor-β1/Smad singaling Pathway (TGF-β1/Smads), remarkably improve the pathological lesion of renal tissue, protect the remaining nephron, retard renal fibrosis.
方法：提出慢性肾衰竭厥阴阴枢不利的病机假说,以和厥阴法为治疗大法,精选药物,合理组方,制成和络泄浊颗粒,进行实验研究；采用5/6肾切除大鼠模型,将60例Wistar大鼠随机分为6组：正常组、模型组、西药福辛普利组、中药低剂量组、中剂量组及高剂量组。检测各组血清尿素氮(BUN)、血清肌酐(Scr),取残肾组织行HE染色,光镜观察肾组织病理变化,免疫组化检测细胞外基质的主要成分纤维蛋白(FN)表达的变化。逆转录聚合酶链反应(RT-PCR)及免疫组化检测转化生长因子β1(TGF-β1)、p-Smad2/3、Smad7基因及蛋白表达的变化。
结果：和络泄浊颗粒与福辛普利治疗组BUN、Scr水平明显低于模型组(P<0.05)；中西药治疗组大鼠5/6肾切除后肾组织TGF-β1、p-Smad2/3表达减弱,Smad7表达增强,肾组织FN沉积减少,肾小球硬化改善(P<0.05)。
结论：慢性肾衰竭具有厥阴阴枢不利的病机特点,和厥阴法是其重要治法；和络泄浊颗粒可调节TGF-β1/smads信号传导通路,改善肾纤维化时ECM主要成分的沉积,保护残存肾功能,延缓肾纤维化的进展。
Objective:To discusse the correlation of pathogenesis of chronic renal failure (CRF) with Jueyin disease, the thinging of treating chronic renal failure by mediating-Jueyin, and study the mechanism of the method of mediating-Jueyin interfering in renal fibrosis.
Methods:Put fotward the hypothesis that CRF are resulted from Jueyin helm malfunction. Take mediating-Jueyin as treatment method, composing the formula rationally, choosing the medicine carefully, to make the Reconciliating Collaterals and Dispersing Turbid Granula(RDG). Using 5/6 nephrectomy rats divided into 6 groups, which are normal group, model group, treated by Fuxinpuli group, treated by RDG Low-dose group(group I)、RDG middle-dose group(group II) and RDG High-dose group(group III). Observing the weight change of the rat and their biochemical results:blood urea nitrogen(BUN), serum creatinine(Scr). Take the renal tissue from the operative side. HE staining and immunohistochemical methods were used to detect the changes of Fibronectin (FN). immunohistochemical and RT-PCR methods were used to detect the changes of the gene and protein expression of transforming growth factor-β1/Smad singaling Pathway (TGF-β1/Smads).
Result:Compared with the untreated 5/6 nephrectomized group, BUN、Scr of RDG groups and Fuxinpuli group were substantially decreased (P< 0.05). The expression of TGF-β1、p-Smad2/3、FN in 5/6 nephrectomy rats is higher than in normal group. It was less in RDG groups and Fuxipuli group (P< 0.05).The expression of Smad7 in 5/6 nephrectomy rats is less than in normal group. It was higher in RDG groups and Fuxipuli group (P< 0.05). extracellular matrix(ECM) was less in RDG groups and Fuxipuli group. The glomerular sclerosis was less in RDG groups and Fuxipuli group.
Conclusion:The Jueyin helm malfunction is the pathological characteristic of CRF, the method of mediating-Jueyin is effective on it. The therapy can adjust transforming growth factor-β1/Smad singaling Pathway (TGF-β1/Smads), remarkably improve the pathological lesion of renal tissue, protect the remaining nephron, retard renal fibrosis.
引文
[1]王琦.关于《伤寒论》“厥阴病”的讨论.新中医,1979；(6)：18.
[2]李培生.《伤寒论讲义》.上海：上海科学技术出版社,1985,第五版：189.
[3]李富汉.《伤寒论》厥阴病探要.河南中医,1994；(1)：2-4.
[4]岳在文.《伤寒论》厥阴病古今认识述评,北京中医杂志,1985；(6)：46-48.
[5]姚荷生.《伤寒论》的难解篇章一厥阴篇,江西中医学院学报,1989；2(1)：5-8.
[6]陈克正.从易理和临床认识《伤寒论》厥阴病.中国医药学报,1995；(2)：20-21.
[7]姜建国.《伤寒论释难》.上海：上海中医药大学出版社,2007,第一版：280.
[8]俞长荣.对厥阴病篇条文的再研讨.湖北中医杂志.1984；(4)：5-6.
[9]钱超尘.伤寒论文献通考.北京：学苑出版社,1993,第一版：453-456.
[10]姜建国.《伤寒论释难》.上海：上海中医药大学出版社,2007；第一版：236.
[11]刘英锋.以厥阴主风理论指导乌梅丸的推广应用.中医杂志,1998；39(1)：15.
[12]邓家纲.“罢极之本”实义辨析.广西中医药,1987；10(1)：41-44.
[13]于俊生.肾脏病经方论治.北京：人民卫生出版社,2007.第一版：35.
[14]王钢,陈以平,邹燕勤.现代中医肾脏病学.北京：人民卫生出版社,2003,第一版：870.
[15]肖相如.肾病中的瘀血.辽宁中医杂志,2003；30(2)：85.
[16]于俊生,刘丙欣.和络泄浊方对肾间质纤维化大鼠转化生长因子β1表达的影响中医药学刊,2006；24(7)：1220-1221.
[17]杨丽丽.当归芍药散临床应用体会.浙江中西医结合杂志,2010；20(1)：38-40.
[18]黄斌,王东华.当归芍药散临床运用心得.中国临床医生,2010；38(9)：67.
[19]常建文,刘永庆.当归芍药散在妇科的临床应用.中医药临床杂志,2010；22(3)：205-206.
[20]董晋莉,朱颖.当归芍药散合桂枝茯苓丸加味治疗慢性盆腔炎40例.吉林中医药,2007,6(6)：32.
[21]潘红燕.当归芍药散加味治疗输卵管积水129例.江西中医药,2007；5(5)：44.
[22]黄凌,周超杰,梁芳林,等.当归芍药散治疗艾滋病HAART疗法肝功能损害48例.中医研究,2007；8(8)：55-56.
[23]柳江.当归芍药散加味治疗血管性头痛临床研究.临床合理用药,2009；2(21)：46.
[24]王莉.当归芍药散加味治疗颈性眩晕临床研究.医学信息,2010；5：237.
[25]杨顺利.当归芍药散加味治疗乙肝后肝硬化腹水40例疗效观察.中国现代医生,2009；47(32)：83-84.
[26]王燕萍,王永贞.当归芍药散结合西药治疗脑梗塞60例.光明中医,2009；24(4)：749-750.
[27]徐建龙,孙红颖.聂莉芳教授运用当归芍药散治疗特发性水肿的经验.辽宁中医药大学学报,2009；11：88-89.
[28]杜积慧.侯爱画.当归芍药散治疗Graves病40例疗效观察.山东中医杂志,2007；1(1)：26-27.
[29]王热闹,薛彩莲.当归芍药散临床新用.四川中医,2003；21(2)：79.
[30]龚长根.当归芍药散在男科中的应用.中国民间疗法,2009；17(9)：38-39.
[31]管仲安.当归芍药散加局部封闭治疗肛裂31例.陕西中医,1990；11(5)：211.
[32]熊晓刚.加味当归芍药散治疗面部黄褐斑35例.河北中医,2000；22(4)：295.
[33]苏利霞,薛红梅.当归芍药散加味治疗乳腺增生症102例疗效观察.河南中医药学刊,2002；17(6)：48.
[34]刘国云,迟晓丽,马渊,等.当归芍药散活性部位DSS-A-N-30对大鼠离体子宫平滑肌收缩的影响.中国药理学与毒理学杂志,2007；21(5)：427-433.
[35]胡兵,董晓蕾.当归芍药散拮抗雷公藤对雌鼠生殖系统影响的实验研究.时珍国医国药,2000；11(9)：775-776.
[36]周永禄.当归芍药散的药理研究.中成药,1991；13(12)：28.
[37]谢春光,蓝肇熙.当归芍药散对痛经患者的血液流变性及PGF2α水平的影响.中西医结合杂志,1990；10(7)：410.
[38]阎艳丽,于永军,宋晓宇,等.当归芍药散及煎剂对异丙肾上腺素所致大鼠心肌缺血的影响.辽宁中医杂志,2006；3(9)：1203-1204.
[39]寇俊萍,高志领,刘中,等.当归芍药散对小鼠学习记忆及脑内SOD、MDA的影响.中国试验方剂学杂志,1997；3(4)：24-27.
[40]马世平,詹莹,瞿融.当归芍药散的抗氧化作用研究.中药药理与临床,2001；17(3)：1.
[41]周件贵.当归芍药散的组方和药理药效研究.中成药,1996；7(2)：47.
[42]寇俊萍,华敏,严永清.当归芍药散对小鼠免疫功能的影响.中国现代应用药学, 2003；20(3)：171.
[43]Raij L,Azar S,Keane W. Mesangial immune injury,hypertension, and progessive glomerular damage in Dahl rats. Kidney Int,1984;26:137-143.
[44]尤燕舞,丁国华,陈铖.苯那普利对阿霉素肾病大鼠肾皮质Smad3、Smad7表达的影响.实用医学杂志,2004；20(1)：14-16.
[45]Fries KL,Miller WE,Raab-Traub,et al. The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1(LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology,1999;264(1):159-166.
[46]傅文录.专科专病名医临证经验丛书—肾脏病.北京：人民卫生出版社,2002,第1版：337.
[47]谢永祥,龙春莉,浊毒与肾纤维化浅析.广西中医药,2009；32(6)：25-26.
[48]赵宗江,牛建昭,杨美娟.等.5/6肾切除大鼠肾脏病理图象分析与中医证型的研究.中国中西医结合肾病杂志,2002；3(4)：199-201.
[49]Kang DH, Kanellis J,Hugo C,et al.Role of t he microvascular endothelium in progressive renal disease.J Am Soc Nephrol,2002;13(3):806-816.
[50]王永钧,张敏鸥.痰瘀互结与肾内微型癥积.中国中西医结合肾病杂志,2003,4(1)：1-3.
[51]张光荣.肾小球硬化中医病机探讨.江西中医药,2002；33(3)：48-49.
[52]杜雨茂.中国百年百名中医临床家丛书—杜雨茂.北京：中国中医药出版社,2003：12.
[53]曹柏龙,缪娟.尿毒症呕吐可以从厥阴经辨证论治.中国科技信息,2005；(12)：166-167.
[54]钟建,史伟,吴金玉.肾纤维化的中医机制及其干预靶点,辽宁中医杂志,2010；37(9)：1695-1696.
[55]殷苏燕.健脾泄浊化瘀合剂治疗早中期慢性肾衰临床观察.北京中医.2001；(5)：13-14.
[56]苏路侠,钟百灵.和解益肾化瘀解毒法治疗慢性肾功能衰竭71例临床观察.中医杂志,2004；45(8)：590-592.
[57]朱戎.活血中药干预肾纤维化的实验研究进展.江苏中医药,2005；26(6)：57.
[58]瓮孝刚,窦敬芳.百令胶囊对实验性糖尿病大鼠肾脏的保护作用.中华实用中西医 杂志,2005；18(21)：1475.
[59]陈清江,杨丽,王辉,等.黄芪对人肾间质成纤维细胞增殖和转化因子-β1mRNA表达的影响.郑州大学学报(医学版),2005；40(5)：871-873.
[60]严海东,李雪竹,李蔓.银杏叶提取物对肾间质成纤维细胞中AGEs诱导的TGF-β1、CTGF表达及氧化应激的抑制作用.中国实用内科杂志,2006；26(3)：443.
[61]黄海长,闵亚丽,李惊子,等.黄芪当归合剂及依那普利对结缔组织转化生长因子在肾间质纤维化中表达的比较研究.中华肾脏病杂志,2003；19(3)：133.
[62]王军,程晓霞,杨汝春,等.复方积雪草对局灶硬化性肾小球肾炎模型小鼠肾组织内细胞因子表达的调控作用.中国临床药理学与治疗学,2003；8(6)：638.
[63]胡家才,夏明珠,万青松.归芪口服液抗大鼠肾间质纤维化的实验研究.武汉大学学报,2005；26(4)：491.
[64]赵贤俊,李才,邓悦,等.解毒通络保肾胶囊对糖尿病大鼠肾脏的保护作用.中国中医基础医学杂志,2003；9(8)：26.
[65]何立群,王怡,高建东.抗纤灵冲剂对慢性肾衰肾纤维化及其影响因素的研究.科研成果,2003；32(7)：20.
[66]张长明,何立群,黄中迪.抗纤灵冲剂对肾缺血-再灌注大鼠抗氧化系统的影响.中国中西医结合肾病杂志,2002；3(2)：74-76.
[67]Inoki K,Haneda M,Ishida T.etal. Kidney Int,2000,58(suppl77):s76-s80
[68]Eddy AA. Molecular basis renal fibrosis. Pediatr Nephrol,2000;15 (34):290-301.
[69]Bucala R. Fibrocytes:discovery of a circulating connective tissue cell progenitor. In: Bucala R (ed). New insights into tissue repair and systemic fibroses. World Scie-ntific:Singapore,2007;1:1-18.
[70]Varcoe RL, MikhailM, Guiffre AK, et al. The role of the fibrocytein intimal hyperplasia. J Thromb Haemost,2006;4:1125-1133.
[71]Martine B, Harmsen MC, van Luyn MJA, et al. Bone marrow derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen Ⅰ after is chemia/reperfusion inrats. Am J Soc Nephrol,2007;18:165-175.
[72]Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol,2005; 16(1):68278.
[73]Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol,2001; 159(4):1465-1475.
[74]Yang J, Shultz RW, Mars WM, et al. Disruption of tissue-typeplasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest,2002;110(10):1525-1538.
[75]Poncelet AC,de Caestecker MP,Schnaper HW. The transforming growth TGF-β/ SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int,1999;56(4):1354-1365.
[76]Sakai N, Wada T, Furuichi K, et al. MCP-1/CCR-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J Leukoc Biol,2006; 79:555-563.
[77]Kagami S, Kuhara T, Yasutomo K, et al. transforming growth factor-beta stimulates the expression of betal integrins and adhesion by rat mesangial cells. Exp Cell Res,2003;229(1):1.
[78]Chen R,Huang C,Morinelli TA,et al. Blockade of the effects of factor-β1 on mesangial cells by over expression of Smad7. J Am Soc Nephrol,2002;13(4):887-893.
[79]Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest,2001;108(6):807-816.
[80]Hionoby T, Hionobu MO1 Pathogenesis of fibrosis role of TGF-β and CTGF.Current Opinin,2002; 14(6):681-685.
[81]张海燕,李幼姬,侯赛云,等.结缔组织生长因子在单侧输尿管梗阻大鼠肾组织中的表达.中国病理生理杂志,2006；22(3)：427-430.
[82]Yokoi H, Mukoyama M, Nagae T, et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitalfibrosis.Am Soc Nephrol,2004;15(6):1430-1440
[83]Yu H,Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000,92(18):1472-1489
[84]Senthil D,Choudhury GG,Abboud HE, et al. Regulation of protein synthesis by IGF-I in proximal tubular epithelial cells. Am J Physiol Renal Physiol 2002;283(6):1226-1236.
[85]Lam S, van der Gees t RN, Verhagen NA, et al. Connective tissue growth factor and IGF-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 2003;52(12):2975-2983.
[86]Ballermann BJ. Regulation of bovine glomerular endothelial cell growth in vitro. Am J Physiol,1989;256:C182-189.
[87]Strutz F, ZeisbergM, Hemmerlein B, et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and maymediate autocrine fibroblast proliferation. Kidney Int,2000;57:1521-1538.
[88]Khwaja A, El KossiM, Floege J, et al. The management of CKD:A look into the future. Kidney Int,2007;72:1316-1323.
[89]Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-relatelated events and synthesis of matrix proteinsin renam interstitial fibroblasts. Kidney Int, 1997;52(6):1497-1510.
[90]罗海清,梁东,刘华锋.肾间质纤维化的形成机制及中药防治作用.中国中西医结合肾病杂志,2004；5(7)：432.
[91]Rastaldi MP, Ferraio F, Giardino L, et al. Epithelial mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int,2002;62(3):137-146.
[92]黄志文,梁东,唐德遷,等.细胞外基质降解酶系和肾间质纤维化.国外医学：泌尿系统分册,2004；24(3)：416.
[93]Gretz N, Floege J, Sugenoya Y,et al. Nutritional treatment of CRF. AM J Nephrol,1989;61:147-150.
[94]Sterner G, Wennberg A. Partial nephrectomy and chronic renal failure, the "adult" rat model. ContrNephrol,1988;60:3940.
[95]Ritz E, Furst P, Yoshimura A. The role of the parathroid glands in the uremic syndrome.Am J Kidney Dis,1995;26:(5):808-811.
[96]沈延春,杨晓,陈琼霞.5/6肾切除大鼠肾脏病理学动态变化.上海实验动物科学,2005；25(1)：21-24.
[97]Barata K, Yoshida M, Hokao R,et al.Function in 5/6 nephrectomized ratsbasic study for renal toxicity using 5/6 nephrectomized rats. J Toxicol Sci,1998;23(5):433-442.
[98]Zoja C,Corna D,Camozzi D et al. How to fully protect the kidney in a severe model of progressive nephropathy:A multidrug approach. J Am Soc Nephro,2002;13(12): 2898-2908.
[99]张瑶,于力,郝志宏,等.福辛普利对肾小球系膜细胞TGF-β1/Smad信号通路的干预作用.临床儿科杂志,2010；28(3)：269-273.
[100]胡志娟,李英,何伟,等.贝那普利对糖尿病大鼠肾组织中TGF-β1和Smad4表达 的影响.华北国防医药,2005；17(2)：77-81.
[101]宁旺斌,胡静,陶立坚.氯沙坦对5/6肾切除大鼠残余肾组织中TGF-β1,p-Smad2/3及Smad7的作用.中南大学学报(医学版),2007；32(6)：1007-1012.
[102]李莉华,邬丽莎,赵春玲.兔肾缺血再灌注损伤时TNF-a、IL-6和bFGF的变化及当归的影响.中国病理生理杂志,2002；18(9)：1119-1121.
[103]郑鸿翱,姚欣耀,盛楚华等.当归或三七对兔甘油致急性肾衰的保护作用及其机制研究.中国现代医学杂志,2003；13(9)：36.
[104]从莉萍,刘庆彦,赵凯华.当归对糖尿病肾病的保护作用.现代医药卫生,2004；20(14)：1351.
[105]李民,李俊卿,胡毅.川芎和川芎嗪对环孢素A肾中毒的作用比较,中华泌尿外科杂志,1997；]8(4)：201-204.
[106]王亚平,李伯祥.川芎嗪防治肾间质纤维化作用的实验研究.中国中西医结合肾病杂志,2002；3(2)：77-78.
[107]吴家斌,舒贵扬.赤芍对肾病综合征患者血脂和血液流变学的影响.中药药理与临床,2001；17(1)：45-46.
[108]吴望明,吴应建.赤芍总苷对大鼠肾缺血再灌注损伤的保护作用研究.湖南中医杂志,2004；20(3)：68-69.
[109]朱慧民,祝彼得.赤芍对实验性血管成形术后胶原纤维分布种类及含量的影响.中药药理与临床,2004；20(2)：18-19.
[110]李延昌,孙玉凤,冯志杰.赤芍抗肝纤维化的实验研究.中国中西医结合杂志,2003；23(10)：767-768.
[111]黄翠玲,李才,邓义斌.大黄延缓慢性肾功能衰竭机制的研究进展.中国中西医结合杂志,1995；5(8)：506.
[112]王晓玲,王俭勤,夏延龄.大黄素对人肾成纤维细胞抑制作用的研究.中国中西医结合肾病杂志,2002；3(1)：629-631.
[113]张杰,屈燧林,王剑勤.大黄素对血管紧张素Ⅱ刺激人肾成纤维细胞增殖、胶原表达的抑制效应研究.四川医学,2002；23(11)：1114-1117.
[114]王军,鲁盈,杨汝春.大黄素防治糖尿病大鼠早期肾损伤的实验研究.浙江医学,2000；22(12)：723-726.
[115]郭啸华,刘志红,戴春笋等.大黄酸抑制TGF-β1诱导的肾小管上皮细胞肥大及细 胞外基质产生.肾脏病与透析肾移植杂志,2001；10(2)：101.
[116]王常青,杨桂兰.两种海藻多糖对大鼠脂质代谢和血小板功能的比较,中华预防医学杂志,1997；31(6)：342-345.
[117]吴丽明,张敏.土茯苓中落新妇苷的利尿和镇痛作用.中药材,1995；18(12)：627.
[118]于俊生,刘丙欣,宗瑞杰.和络泄浊方对肾间质纤维化大鼠细胞外基质的调控作用.中国中西医结合肾病杂志,2007；8(1)：14-17.
[119]于俊生,刘海军,刘先英.和络泄浊方对肾间质纤维化大鼠MMP-9 TIMP-1基因表达的影响.辽宁中医杂志,2007；34(10)：1375-1377.
[120]冯广青,于俊生,吴璟.和络泄浊方治疗慢性肾功能衰竭60例疗效观察.山东医药,2007；47(20)：100-101.
[121]Magnusson,MK,Mosher,VF. Fibronectin structure, assembly, and cardiovascular implications Arterioscler. Thromb Vase Biol,1998;18:1363.
[122]Johnson TS, Haylor JL,Thomas GL,et al.Matrix metalloproteinasesand their inhibitions in experimental renal scarring. ExpNephrol,2002; 10(3):182-195.
[123]YangY. Zhang SY, Sich M, et al. Glomerular extracellular matrixand growth factor in diffuse mesangial sclerosis. Pediatr Nephrol,2001,16(5):429-438.
[124]Van VlietA, BaeldeHJ, VlemingLJ, et al. Distribution of fibronect in isoforms in human renal disease. J Pthol,2001; 193:256.
[125]Waiser J, Dell Q, Bohler T, et al. Cyclosprine A up-regulates the expression of TGF-beta 1 and its receptor I andtype Ⅱ in rat mesangial cells. Nephrol Dial Transplant,2002;17(9):1568-1577.
[126]Kim J H, Kim B K, Moon K C, et al. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int,2003; 64(5):1715-1721.
[127]Massague J, Blain SW, Lo RS. TGF-β signaling in growth control, cancer, and heritable disorder. Cell,2000;103(2):295-309.
[128]Zimmerman CM, Padgett RW. Transforming growth factor β signaling mediators and modulator. Gene,2000;249(1/2):17-30.
[129]Runyan CE, Poncelet AC, Schnaper HW, et al. TGF-β receptor-binding proteins: complex interactions.Cell Signal,2006;18(12):2077-2088.
[130]Taal MW, Zandi-Nejad K, Weening B, et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int,2000;58 (4):1664- 1676.
[131]Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-beta receptor for degradation. Mol Cell,2000;6(6):1365-1375.
[132]Hou C C,WangW, Huang X R, et al. Ultrasound-microbub-ble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol,2005;166(3):761-771.
[2]李培生.《伤寒论讲义》.上海：上海科学技术出版社,1985,第五版：189.
[3]李富汉.《伤寒论》厥阴病探要.河南中医,1994；(1)：2-4.
[4]岳在文.《伤寒论》厥阴病古今认识述评,北京中医杂志,1985；(6)：46-48.
[5]姚荷生.《伤寒论》的难解篇章一厥阴篇,江西中医学院学报,1989；2(1)：5-8.
[6]陈克正.从易理和临床认识《伤寒论》厥阴病.中国医药学报,1995；(2)：20-21.
[7]姜建国.《伤寒论释难》.上海：上海中医药大学出版社,2007,第一版：280.
[8]俞长荣.对厥阴病篇条文的再研讨.湖北中医杂志.1984；(4)：5-6.
[9]钱超尘.伤寒论文献通考.北京：学苑出版社,1993,第一版：453-456.
[10]姜建国.《伤寒论释难》.上海：上海中医药大学出版社,2007；第一版：236.
[11]刘英锋.以厥阴主风理论指导乌梅丸的推广应用.中医杂志,1998；39(1)：15.
[12]邓家纲.“罢极之本”实义辨析.广西中医药,1987；10(1)：41-44.
[13]于俊生.肾脏病经方论治.北京：人民卫生出版社,2007.第一版：35.
[14]王钢,陈以平,邹燕勤.现代中医肾脏病学.北京：人民卫生出版社,2003,第一版：870.
[15]肖相如.肾病中的瘀血.辽宁中医杂志,2003；30(2)：85.
[16]于俊生,刘丙欣.和络泄浊方对肾间质纤维化大鼠转化生长因子β1表达的影响中医药学刊,2006；24(7)：1220-1221.
[17]杨丽丽.当归芍药散临床应用体会.浙江中西医结合杂志,2010；20(1)：38-40.
[18]黄斌,王东华.当归芍药散临床运用心得.中国临床医生,2010；38(9)：67.
[19]常建文,刘永庆.当归芍药散在妇科的临床应用.中医药临床杂志,2010；22(3)：205-206.
[20]董晋莉,朱颖.当归芍药散合桂枝茯苓丸加味治疗慢性盆腔炎40例.吉林中医药,2007,6(6)：32.
[21]潘红燕.当归芍药散加味治疗输卵管积水129例.江西中医药,2007；5(5)：44.
[22]黄凌,周超杰,梁芳林,等.当归芍药散治疗艾滋病HAART疗法肝功能损害48例.中医研究,2007；8(8)：55-56.
[23]柳江.当归芍药散加味治疗血管性头痛临床研究.临床合理用药,2009；2(21)：46.
[24]王莉.当归芍药散加味治疗颈性眩晕临床研究.医学信息,2010；5：237.
[25]杨顺利.当归芍药散加味治疗乙肝后肝硬化腹水40例疗效观察.中国现代医生,2009；47(32)：83-84.
[26]王燕萍,王永贞.当归芍药散结合西药治疗脑梗塞60例.光明中医,2009；24(4)：749-750.
[27]徐建龙,孙红颖.聂莉芳教授运用当归芍药散治疗特发性水肿的经验.辽宁中医药大学学报,2009；11：88-89.
[28]杜积慧.侯爱画.当归芍药散治疗Graves病40例疗效观察.山东中医杂志,2007；1(1)：26-27.
[29]王热闹,薛彩莲.当归芍药散临床新用.四川中医,2003；21(2)：79.
[30]龚长根.当归芍药散在男科中的应用.中国民间疗法,2009；17(9)：38-39.
[31]管仲安.当归芍药散加局部封闭治疗肛裂31例.陕西中医,1990；11(5)：211.
[32]熊晓刚.加味当归芍药散治疗面部黄褐斑35例.河北中医,2000；22(4)：295.
[33]苏利霞,薛红梅.当归芍药散加味治疗乳腺增生症102例疗效观察.河南中医药学刊,2002；17(6)：48.
[34]刘国云,迟晓丽,马渊,等.当归芍药散活性部位DSS-A-N-30对大鼠离体子宫平滑肌收缩的影响.中国药理学与毒理学杂志,2007；21(5)：427-433.
[35]胡兵,董晓蕾.当归芍药散拮抗雷公藤对雌鼠生殖系统影响的实验研究.时珍国医国药,2000；11(9)：775-776.
[36]周永禄.当归芍药散的药理研究.中成药,1991；13(12)：28.
[37]谢春光,蓝肇熙.当归芍药散对痛经患者的血液流变性及PGF2α水平的影响.中西医结合杂志,1990；10(7)：410.
[38]阎艳丽,于永军,宋晓宇,等.当归芍药散及煎剂对异丙肾上腺素所致大鼠心肌缺血的影响.辽宁中医杂志,2006；3(9)：1203-1204.
[39]寇俊萍,高志领,刘中,等.当归芍药散对小鼠学习记忆及脑内SOD、MDA的影响.中国试验方剂学杂志,1997；3(4)：24-27.
[40]马世平,詹莹,瞿融.当归芍药散的抗氧化作用研究.中药药理与临床,2001；17(3)：1.
[41]周件贵.当归芍药散的组方和药理药效研究.中成药,1996；7(2)：47.
[42]寇俊萍,华敏,严永清.当归芍药散对小鼠免疫功能的影响.中国现代应用药学, 2003；20(3)：171.
[43]Raij L,Azar S,Keane W. Mesangial immune injury,hypertension, and progessive glomerular damage in Dahl rats. Kidney Int,1984;26:137-143.
[44]尤燕舞,丁国华,陈铖.苯那普利对阿霉素肾病大鼠肾皮质Smad3、Smad7表达的影响.实用医学杂志,2004；20(1)：14-16.
[45]Fries KL,Miller WE,Raab-Traub,et al. The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1(LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology,1999;264(1):159-166.
[46]傅文录.专科专病名医临证经验丛书—肾脏病.北京：人民卫生出版社,2002,第1版：337.
[47]谢永祥,龙春莉,浊毒与肾纤维化浅析.广西中医药,2009；32(6)：25-26.
[48]赵宗江,牛建昭,杨美娟.等.5/6肾切除大鼠肾脏病理图象分析与中医证型的研究.中国中西医结合肾病杂志,2002；3(4)：199-201.
[49]Kang DH, Kanellis J,Hugo C,et al.Role of t he microvascular endothelium in progressive renal disease.J Am Soc Nephrol,2002;13(3):806-816.
[50]王永钧,张敏鸥.痰瘀互结与肾内微型癥积.中国中西医结合肾病杂志,2003,4(1)：1-3.
[51]张光荣.肾小球硬化中医病机探讨.江西中医药,2002；33(3)：48-49.
[52]杜雨茂.中国百年百名中医临床家丛书—杜雨茂.北京：中国中医药出版社,2003：12.
[53]曹柏龙,缪娟.尿毒症呕吐可以从厥阴经辨证论治.中国科技信息,2005；(12)：166-167.
[54]钟建,史伟,吴金玉.肾纤维化的中医机制及其干预靶点,辽宁中医杂志,2010；37(9)：1695-1696.
[55]殷苏燕.健脾泄浊化瘀合剂治疗早中期慢性肾衰临床观察.北京中医.2001；(5)：13-14.
[56]苏路侠,钟百灵.和解益肾化瘀解毒法治疗慢性肾功能衰竭71例临床观察.中医杂志,2004；45(8)：590-592.
[57]朱戎.活血中药干预肾纤维化的实验研究进展.江苏中医药,2005；26(6)：57.
[58]瓮孝刚,窦敬芳.百令胶囊对实验性糖尿病大鼠肾脏的保护作用.中华实用中西医 杂志,2005；18(21)：1475.
[59]陈清江,杨丽,王辉,等.黄芪对人肾间质成纤维细胞增殖和转化因子-β1mRNA表达的影响.郑州大学学报(医学版),2005；40(5)：871-873.
[60]严海东,李雪竹,李蔓.银杏叶提取物对肾间质成纤维细胞中AGEs诱导的TGF-β1、CTGF表达及氧化应激的抑制作用.中国实用内科杂志,2006；26(3)：443.
[61]黄海长,闵亚丽,李惊子,等.黄芪当归合剂及依那普利对结缔组织转化生长因子在肾间质纤维化中表达的比较研究.中华肾脏病杂志,2003；19(3)：133.
[62]王军,程晓霞,杨汝春,等.复方积雪草对局灶硬化性肾小球肾炎模型小鼠肾组织内细胞因子表达的调控作用.中国临床药理学与治疗学,2003；8(6)：638.
[63]胡家才,夏明珠,万青松.归芪口服液抗大鼠肾间质纤维化的实验研究.武汉大学学报,2005；26(4)：491.
[64]赵贤俊,李才,邓悦,等.解毒通络保肾胶囊对糖尿病大鼠肾脏的保护作用.中国中医基础医学杂志,2003；9(8)：26.
[65]何立群,王怡,高建东.抗纤灵冲剂对慢性肾衰肾纤维化及其影响因素的研究.科研成果,2003；32(7)：20.
[66]张长明,何立群,黄中迪.抗纤灵冲剂对肾缺血-再灌注大鼠抗氧化系统的影响.中国中西医结合肾病杂志,2002；3(2)：74-76.
[67]Inoki K,Haneda M,Ishida T.etal. Kidney Int,2000,58(suppl77):s76-s80
[68]Eddy AA. Molecular basis renal fibrosis. Pediatr Nephrol,2000;15 (34):290-301.
[69]Bucala R. Fibrocytes:discovery of a circulating connective tissue cell progenitor. In: Bucala R (ed). New insights into tissue repair and systemic fibroses. World Scie-ntific:Singapore,2007;1:1-18.
[70]Varcoe RL, MikhailM, Guiffre AK, et al. The role of the fibrocytein intimal hyperplasia. J Thromb Haemost,2006;4:1125-1133.
[71]Martine B, Harmsen MC, van Luyn MJA, et al. Bone marrow derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen Ⅰ after is chemia/reperfusion inrats. Am J Soc Nephrol,2007;18:165-175.
[72]Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol,2005; 16(1):68278.
[73]Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol,2001; 159(4):1465-1475.
[74]Yang J, Shultz RW, Mars WM, et al. Disruption of tissue-typeplasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest,2002;110(10):1525-1538.
[75]Poncelet AC,de Caestecker MP,Schnaper HW. The transforming growth TGF-β/ SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int,1999;56(4):1354-1365.
[76]Sakai N, Wada T, Furuichi K, et al. MCP-1/CCR-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J Leukoc Biol,2006; 79:555-563.
[77]Kagami S, Kuhara T, Yasutomo K, et al. transforming growth factor-beta stimulates the expression of betal integrins and adhesion by rat mesangial cells. Exp Cell Res,2003;229(1):1.
[78]Chen R,Huang C,Morinelli TA,et al. Blockade of the effects of factor-β1 on mesangial cells by over expression of Smad7. J Am Soc Nephrol,2002;13(4):887-893.
[79]Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest,2001;108(6):807-816.
[80]Hionoby T, Hionobu MO1 Pathogenesis of fibrosis role of TGF-β and CTGF.Current Opinin,2002; 14(6):681-685.
[81]张海燕,李幼姬,侯赛云,等.结缔组织生长因子在单侧输尿管梗阻大鼠肾组织中的表达.中国病理生理杂志,2006；22(3)：427-430.
[82]Yokoi H, Mukoyama M, Nagae T, et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitalfibrosis.Am Soc Nephrol,2004;15(6):1430-1440
[83]Yu H,Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000,92(18):1472-1489
[84]Senthil D,Choudhury GG,Abboud HE, et al. Regulation of protein synthesis by IGF-I in proximal tubular epithelial cells. Am J Physiol Renal Physiol 2002;283(6):1226-1236.
[85]Lam S, van der Gees t RN, Verhagen NA, et al. Connective tissue growth factor and IGF-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 2003;52(12):2975-2983.
[86]Ballermann BJ. Regulation of bovine glomerular endothelial cell growth in vitro. Am J Physiol,1989;256:C182-189.
[87]Strutz F, ZeisbergM, Hemmerlein B, et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and maymediate autocrine fibroblast proliferation. Kidney Int,2000;57:1521-1538.
[88]Khwaja A, El KossiM, Floege J, et al. The management of CKD:A look into the future. Kidney Int,2007;72:1316-1323.
[89]Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-relatelated events and synthesis of matrix proteinsin renam interstitial fibroblasts. Kidney Int, 1997;52(6):1497-1510.
[90]罗海清,梁东,刘华锋.肾间质纤维化的形成机制及中药防治作用.中国中西医结合肾病杂志,2004；5(7)：432.
[91]Rastaldi MP, Ferraio F, Giardino L, et al. Epithelial mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int,2002;62(3):137-146.
[92]黄志文,梁东,唐德遷,等.细胞外基质降解酶系和肾间质纤维化.国外医学：泌尿系统分册,2004；24(3)：416.
[93]Gretz N, Floege J, Sugenoya Y,et al. Nutritional treatment of CRF. AM J Nephrol,1989;61:147-150.
[94]Sterner G, Wennberg A. Partial nephrectomy and chronic renal failure, the "adult" rat model. ContrNephrol,1988;60:3940.
[95]Ritz E, Furst P, Yoshimura A. The role of the parathroid glands in the uremic syndrome.Am J Kidney Dis,1995;26:(5):808-811.
[96]沈延春,杨晓,陈琼霞.5/6肾切除大鼠肾脏病理学动态变化.上海实验动物科学,2005；25(1)：21-24.
[97]Barata K, Yoshida M, Hokao R,et al.Function in 5/6 nephrectomized ratsbasic study for renal toxicity using 5/6 nephrectomized rats. J Toxicol Sci,1998;23(5):433-442.
[98]Zoja C,Corna D,Camozzi D et al. How to fully protect the kidney in a severe model of progressive nephropathy:A multidrug approach. J Am Soc Nephro,2002;13(12): 2898-2908.
[99]张瑶,于力,郝志宏,等.福辛普利对肾小球系膜细胞TGF-β1/Smad信号通路的干预作用.临床儿科杂志,2010；28(3)：269-273.
[100]胡志娟,李英,何伟,等.贝那普利对糖尿病大鼠肾组织中TGF-β1和Smad4表达 的影响.华北国防医药,2005；17(2)：77-81.
[101]宁旺斌,胡静,陶立坚.氯沙坦对5/6肾切除大鼠残余肾组织中TGF-β1,p-Smad2/3及Smad7的作用.中南大学学报(医学版),2007；32(6)：1007-1012.
[102]李莉华,邬丽莎,赵春玲.兔肾缺血再灌注损伤时TNF-a、IL-6和bFGF的变化及当归的影响.中国病理生理杂志,2002；18(9)：1119-1121.
[103]郑鸿翱,姚欣耀,盛楚华等.当归或三七对兔甘油致急性肾衰的保护作用及其机制研究.中国现代医学杂志,2003；13(9)：36.
[104]从莉萍,刘庆彦,赵凯华.当归对糖尿病肾病的保护作用.现代医药卫生,2004；20(14)：1351.
[105]李民,李俊卿,胡毅.川芎和川芎嗪对环孢素A肾中毒的作用比较,中华泌尿外科杂志,1997；]8(4)：201-204.
[106]王亚平,李伯祥.川芎嗪防治肾间质纤维化作用的实验研究.中国中西医结合肾病杂志,2002；3(2)：77-78.
[107]吴家斌,舒贵扬.赤芍对肾病综合征患者血脂和血液流变学的影响.中药药理与临床,2001；17(1)：45-46.
[108]吴望明,吴应建.赤芍总苷对大鼠肾缺血再灌注损伤的保护作用研究.湖南中医杂志,2004；20(3)：68-69.
[109]朱慧民,祝彼得.赤芍对实验性血管成形术后胶原纤维分布种类及含量的影响.中药药理与临床,2004；20(2)：18-19.
[110]李延昌,孙玉凤,冯志杰.赤芍抗肝纤维化的实验研究.中国中西医结合杂志,2003；23(10)：767-768.
[111]黄翠玲,李才,邓义斌.大黄延缓慢性肾功能衰竭机制的研究进展.中国中西医结合杂志,1995；5(8)：506.
[112]王晓玲,王俭勤,夏延龄.大黄素对人肾成纤维细胞抑制作用的研究.中国中西医结合肾病杂志,2002；3(1)：629-631.
[113]张杰,屈燧林,王剑勤.大黄素对血管紧张素Ⅱ刺激人肾成纤维细胞增殖、胶原表达的抑制效应研究.四川医学,2002；23(11)：1114-1117.
[114]王军,鲁盈,杨汝春.大黄素防治糖尿病大鼠早期肾损伤的实验研究.浙江医学,2000；22(12)：723-726.
[115]郭啸华,刘志红,戴春笋等.大黄酸抑制TGF-β1诱导的肾小管上皮细胞肥大及细 胞外基质产生.肾脏病与透析肾移植杂志,2001；10(2)：101.
[116]王常青,杨桂兰.两种海藻多糖对大鼠脂质代谢和血小板功能的比较,中华预防医学杂志,1997；31(6)：342-345.
[117]吴丽明,张敏.土茯苓中落新妇苷的利尿和镇痛作用.中药材,1995；18(12)：627.
[118]于俊生,刘丙欣,宗瑞杰.和络泄浊方对肾间质纤维化大鼠细胞外基质的调控作用.中国中西医结合肾病杂志,2007；8(1)：14-17.
[119]于俊生,刘海军,刘先英.和络泄浊方对肾间质纤维化大鼠MMP-9 TIMP-1基因表达的影响.辽宁中医杂志,2007；34(10)：1375-1377.
[120]冯广青,于俊生,吴璟.和络泄浊方治疗慢性肾功能衰竭60例疗效观察.山东医药,2007；47(20)：100-101.
[121]Magnusson,MK,Mosher,VF. Fibronectin structure, assembly, and cardiovascular implications Arterioscler. Thromb Vase Biol,1998;18:1363.
[122]Johnson TS, Haylor JL,Thomas GL,et al.Matrix metalloproteinasesand their inhibitions in experimental renal scarring. ExpNephrol,2002; 10(3):182-195.
[123]YangY. Zhang SY, Sich M, et al. Glomerular extracellular matrixand growth factor in diffuse mesangial sclerosis. Pediatr Nephrol,2001,16(5):429-438.
[124]Van VlietA, BaeldeHJ, VlemingLJ, et al. Distribution of fibronect in isoforms in human renal disease. J Pthol,2001; 193:256.
[125]Waiser J, Dell Q, Bohler T, et al. Cyclosprine A up-regulates the expression of TGF-beta 1 and its receptor I andtype Ⅱ in rat mesangial cells. Nephrol Dial Transplant,2002;17(9):1568-1577.
[126]Kim J H, Kim B K, Moon K C, et al. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int,2003; 64(5):1715-1721.
[127]Massague J, Blain SW, Lo RS. TGF-β signaling in growth control, cancer, and heritable disorder. Cell,2000;103(2):295-309.
[128]Zimmerman CM, Padgett RW. Transforming growth factor β signaling mediators and modulator. Gene,2000;249(1/2):17-30.
[129]Runyan CE, Poncelet AC, Schnaper HW, et al. TGF-β receptor-binding proteins: complex interactions.Cell Signal,2006;18(12):2077-2088.
[130]Taal MW, Zandi-Nejad K, Weening B, et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int,2000;58 (4):1664- 1676.
[131]Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-beta receptor for degradation. Mol Cell,2000;6(6):1365-1375.
[132]Hou C C,WangW, Huang X R, et al. Ultrasound-microbub-ble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol,2005;166(3):761-771.